University of Sussex
Browse
JCO-2016-Rugo-JCO.2016.67.1487.pdf (1.07 MB)

Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline

Download (1.07 MB)
journal contribution
posted on 2023-06-09, 02:02 authored by Hope S Rugo, R Bryan Rumble, Erin Macrae, Debra L Barton, Hannah Klein Connolly, Maura N Dickler, Lesley FallowfieldLesley Fallowfield, Barbara Fowble, James N Ingle, Mohammad Jahanzeb, Stephen R D Johnston, Larissa A Korde, James L Khatcheressian, Rita S Mehta, Hyman B Muss, Harold J Burstein
PURPOSE: To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). METHODS: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence. Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with chemotherapy, targeted biologic therapy, and treatment of premenopausal women. This guideline puts forth recommendations for endocrine therapy as treatment for women with HR-positive MBC. RECOMMENDATIONS: Sequential hormone therapy is the preferential treatment for most women with HR-positive MBC. Except in cases of immediately life-threatening disease, hormone therapy, alone or in combination, should be used as initial treatment. Patients whose tumors express any level of hormone receptors should be offered hormone therapy. Treatment recommendations should be based on type of adjuvant treatment, disease-free interval, and organ function. Tumor markers should not be the sole criteria for determining tumor progression; use of additional biomarkers remains experimental. Assessment of menopausal status is critical; ovarian suppression or ablation should be included in premenopausal women. For postmenopausal women, aromatase inhibitors (AIs) are the preferred first-line endocrine therapy, with or without the cyclin-dependent kinase inhibitor palbociclib. As second-line therapy, fulvestrant should be administered at 500 mg with a loading schedule and may be administered with palbociclib. The mammalian target of rapamycin inhibitor everolimus may be administered with exemestane to postmenopausal women with MBC whose disease progresses while receiving nonsteroidal AIs. Among patients with HR-positive, human epidermal growth factor receptor 2-positive MBC, human epidermal growth factor receptor 2-targeted therapy plus an AI can be effective for those who are not chemotherapy candidates.

History

Publication status

  • Published

File Version

  • Published version

Journal

Journal of Clinical Oncology

ISSN

0732-183X

Publisher

American Society of Clinical Oncology

Issue

25

Volume

34

Page range

3069-3103

Department affiliated with

  • Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications

Notes

Journal of clinical oncology : official journal of the American Society of Clinical Oncology J Clin Oncol. 2016 May 23. pii: JCO671487.

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2016-07-05

First Open Access (FOA) Date

2016-11-25

First Compliant Deposit (FCD) Date

2016-07-05

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC